GENNIEFY
Market News
Latest financial news and analysis from global markets
SBUX
Is Starbucks Corporation (SBUX) A Good Stock To Buy Now?
Is SBUX a good stock to buy? We came across a bullish thesis on Starbucks Corporation on Jordan’s Substack. In this article, we will summarize the bulls’ thesis on SBUX. Starbucks Corporation’s share was trading at $97.80 as of April 21st. SBUX’s trailing and forward P/E were 82.46 and 43.67 respectively according to Yahoo Finance. Starbucks Corporation, together with its subsidiaries, […]
W
Wayfair Q1 Earnings Call Highlights
Wayfair (NYSE:W) reported first-quarter 2026 results showing year-over-year revenue growth and improved profitability, while executives emphasized continued market share gains in a home furnishings category they described as still under pressure. Management also highlighted progress in international
BTCUSDT
Is Strategy Inc (MSTR) A Good Stock To Buy Now?
Is MSTR a good stock to buy? We came across a bullish thesis on Strategy Inc on The Analyst’s Journal’s Substack by RA_Capital. In this article, we will summarize the bulls’ thesis on MSTR. Strategy Inc’s share was trading at $170.81 as of April 20th. MSTR’s trailing and forward P/E were 5.30 and 1.29, respectively according to Yahoo Finance. Strategy Inc, […]
INTC
Donald Trump endorsed this stock and the market reacted
There is not a publicly traded company in America quite like this one right now. It is the only stock where the President of the United States logs onto social media to congratulate the country on its returns. That happened on April 30. And the market responded the same way it has every time the ...
V
Is Visa Inc. (V) A Good Stock To Buy Now?
Is V a good stock to buy? We came across a bullish thesis on Visa Inc. on Evangelos Pardalis – Public Portfolio’s Substack by Evangelos Pardalis. In this article, we will summarize the bulls’ thesis on V. Visa Inc.’s share was trading at $313.94 as of April 20th. V’s trailing and forward P/E were 29.48 and 24.39 respectively according to Yahoo […]
NVDA
Missed Advanced Micro Devices' Big Move? Here's Why It's Still a Buy
CEO Lisa Su: Customers are "anxious" to get the MI450 GPU in their data centers.
AMD
Missed Advanced Micro Devices' Big Move? Here's Why It's Still a Buy
CEO Lisa Su: Customers are "anxious" to get the MI450 GPU in their data centers.
INTC
Missed Advanced Micro Devices' Big Move? Here's Why It's Still a Buy
CEO Lisa Su: Customers are "anxious" to get the MI450 GPU in their data centers.
SOFI
1 Mid-Cap Stock for Long-Term Investors and 2 We Avoid
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
VRTX
Halozyme (HALO) Rated Buy on Strong Royalty Growth
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the most profitable biotech stocks to buy now. On April 13, TD Cowen reaffirmed its Buy rating and $96 price target for Halozyme Therapeutics, Inc. (NASDAQ:HALO). The firm forecasts Halozyme to continue to outperform expectations and enhance guidance due to strong growth catalysts such as Vyvgart Hytrulo, Darzalex Faspro, […]
REGN
Piper Sandler Rates Regeneron (REGN) Overweight on Oncology Growth
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ranks among the most profitable biotech stocks to buy now. On April 10, Piper Sandler reaffirmed an Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) with a $875 price target. The assessment followed an Integrated Oncology Day event at the Sylvester Cancer Center in Miami. The event included discussions on oncology therapies […]
VRTX
Vertex (VRTX) Named Top Biotech Pick for 2026 by BofA
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the most profitable biotech stocks to buy now. On April 13, Bank of America reiterated Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) as a top large-cap biotech pick for 2026, with a $598 price objective. The firm stated the company’s cystic fibrosis franchise has the ability to generate cash flow to support […]